MedTrace Logo

Ascending Single-Dose and Multiple-Dose Study to Evaluate RJ4287 in Healthy Subjects

NCT05921006 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2023-07-06

No results posted yet for this study

Summary

A Randomized Study of RJ4287 Drug to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-effect of Single and Multiple Doses in Healthy Volunteers

Conditions

  • Drug Safety

Interventions

DRUG

RJ4287

Oral，tablets，Once daily for 14 days

DRUG

Placebo

Oral，tablets，Once daily daily for 14 days

Sponsors & Collaborators

  • Nanjing Ruijie Pharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-13
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05921006 on ClinicalTrials.gov